Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
DexCom Inc(DXCM)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for DXCM
11/09/2026: DXCM (2-star) is currently NOT-A-BUY. Pass it for now.
DexCom Inc is a prominent medical device company specializing in continuous glucose monitoring (CGM) systems. The company has a leading position in diabetes technology, known for its high-accuracy sensors and deep integration with insulin delivery hardware. Its primary growth opportunity lies in expanding from intensive diabetes care into the large, untapped non-insulin Type 2 diabetes and preventative wellness markets via its Stelo platform. However, DexCom faces intense competitive risks from large medtech rivals like Abbott and Medtronic, along with ongoing challenges regarding healthcare reimbursement and high operating costs. The stock may suit growth-oriented investors, though it carries high price volatility and valuation risk that requires careful monitoring.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | DexCom operates in a high-growth sector with significant penetration potential in non-insulin diabetes and wellness markets. |
| Momentum investor | Mixed fit | Momentum fit is conditional on positive technical trends; the stock often experiences periods of high volatility. |
| Value investor | Weak fit | The stock typically trades at premium valuation multiples consistent with its high growth expectations. |
| Dividend investor | Weak fit | DexCom does not pay a dividend, prioritizing capital reinvestment for growth. |
| Low-risk investor | Weak fit | The stock's high volatility and sensitivity to regulatory and competitive developments make it unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant swings based on quarterly results and clinical trial outcomes. |
| Valuation risk | Medium / high | High P/E ratios mean the stock price is sensitive to changes in growth outlooks. |
| Competition risk (CGM and Diabetes Tech) | High | Aggressive R&D from competitors like Abbott and Medtronic can pressure margins and market share. |
| Business quality | Strong | DexCom possesses strong brand equity and a high-margin, recurring-revenue business model. |
| Dividend income | Low / none | Investors should not expect income, as the company retains all earnings for growth. |
| Execution risk | Medium | Successful scaling of the OTC Stelo platform and software ecosystem is critical to long-term projections. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 18.75% | Avg. Invested days 56 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/09/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 30.24B USD | Price to earnings Ratio 31.92 | 1Y Target Price 98.15 |
Price to earnings Ratio 31.92 | 1Y Target Price 98.15 | ||
Volume (30-day avg) 4.4M shares | Beta 1.44 | 52 Weeks Range 55.84 - 92.59 | Updated Date 11/09/2026 |
52 Weeks Range 55.84 - 92.59 | Updated Date 11/09/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.54 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| CGM Hardware | Wearable sensors and transmitters. | The company makes the bulk of its money from recurring sales of sensors that users replace regularly. |
| Digital & Software | App subscriptions, data sharing, and metabolic health coaching. | DexCom is increasingly building a software layer that generates higher-margin, subscription-based revenue. |
| Geography: United States | Primary revenue generating market. | The U.S. market is the biggest revenue driver and the main focus of its reimbursement strategy. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When After Market | Estimate 0.66 | Actual 0.73 |
Profitability
Profit Margin 19.42% | Operating Margin (TTM) 24.34% |
Management Effectiveness
Return on Assets (TTM) 11.14% | Return on Equity (TTM) 37.67% |
Valuation
Trailing PE 31.92 | Forward PE 25.64 | Enterprise Value 29.19B | Price to Sales(TTM) 5.92 |
Enterprise Value 29.19B | Price to Sales(TTM) 5.92 | ||
Enterprise Value to Revenue 5.72 | Enterprise Value to EBITDA 17.31 | Shares Outstanding 372.95M | Shares Floating 371.59M |
Shares Outstanding 372.95M | Shares Floating 371.59M | ||
Percent Insiders 0.26 | Percent Institutions 107.59 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.